I-Mab (NASDAQ: IMAB) (the “Company”), a US-based, global biotech company, exclusively focused on the development of precision ...
Hosted on MSN2d
Leerink Partners Initiates Coverage of aTyr Pharma (ATYR) with Outperform RecommendationFintel reports that on February 18, 2025, Leerink Partners initiated coverage of aTyr Pharma (NasdaqCM:ATYR) with a ...
Leerink Partners assumed coverage on shares of Atyr PHARMA (NASDAQ:ATYR – Get Free Report) in a research note issued to ...
LUND, SE / ACCESS Newswire / February 19, 2025 /Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm:CANTA) today announced that members of Cantargia's management will participate in one-on-one ...
Over the last decade, as the Institute for Clinical and Economic Review (ICER) has estimated the cost-effectiveness of newly ...
De wijzigingen in financiële projecties en koersdoel zijn een directe reactie op de huidige financiële data en marktomstandigheden die Owens & Minor beïnvloeden. Leerink's analyse wijst op een ...
(Reuters) - The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's popular ...
Op woensdag handhaafde Leerink Partners hun Outperform-rating en koersdoel van $ 13,00 voor aandelen Aquestive Therapeutics (NASDAQ: AQST ), ruim boven de huidige koers van $ 3,06. Analist Roanna Ruiz ...
Leerink Partners cut shares of 10x Genomics (NASDAQ:TXG – Free Report) from an outperform rating to a market perform rating ...
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...
A backdrop of harsh scrutiny on the industry explains sharp market reaction to investigation into UnitedHealth.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback